The global, regional, national burden of laryngeal cancer and its attributable risk factors (1990–2019) and predictions to 2035

Lin, Changwei; Cheng, Wenwei; Liu, Xiajing; Li, Heqing; Song, Yexun

doi:10.1111/ecc.13689

Cited by 14 publications

(15 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We applied the ARIMA and BAPC models (details available elsewhere [ 12 ]) to predict the prevalence rate from 2019 to 2030 for both sexes. The BAPC model has been proven to have higher accuracy in predicting the disease burden, so we used it within an integrated nested Laplacian approximation (R packages BAPC and INLA) to project the prevalence rates from 2019 to 2030 [ 13 , 14 ].…”

Section: Methodsmentioning

confidence: 99%

Downward trends in the global burden of congenital complete hearing loss in children younger than five years from 1990 to 2030

Xiao,

Liu,

Cheng

et al. 2023

J Glob Health

Self Cite

View full text Add to dashboard Cite

Background The global epidemiological data on congenital hearing loss in children is sparse. We aimed to analyse the trends in the burden of complete hearing loss caused by congenital birth defects in children younger than five years from 1990 to 2030. Methods Using data from the Global Burden of Disease (GBD) Study 2019, we reported the counts and rates of prevalence and years lived with disability (YLD) by age, sex, and sociodemographic index (SDI). We also forecasted the prevalence rates until 2030 through the autoregressive integrated moving average (ARIMA) and Bayesian age-period-cohort (BAPC) models. Results We observed a global prevalence rate of 15.4 (95% uncertainty interval (UI) = 5.8 to 33.8) and a YLD rate of 3.3 (95% UI = 1.1 to 7.1) per 100 000 population in 2019, with both showing downward trends from 1990 to 2019. Regionally, Oceania had the highest prevalence (47.2; 95% UI = 18.8 to 96.6) and YLD (10; 95% UI = 3.2 to 22.8) rates, while Central Europe had the lowest rates. Nationally, the prevalence (85.0; 95% UI = 36.8 to 166.8) and YLD (17.9; 95% UI = 6.6 to 36.9) rates were highest in Myanmar and lowest in Peru. Only the United States of America (2.6%; 95% UI = -4.6 to 14.4) and Norway (0.6%; 95% UI = -6.7 to 16.2) showed upward trends. Compared to girls, the prevalence and YLD rates were higher for boys at global, regional, and five SDI quintile levels, except for Eastern Sub-Saharan Africa. At the global level, downward trends were predicted in prevalence rates from 2019 to 2030 between boys and girls. Conclusions Although the global burden of childhood congenital complete hearing loss showed inequalities across locations, sexes, and age groups, we found decreases in the global prevalence rates between 1990 and 2019 and predicted decreases from 2019 to 2030. Better prevention of infectious aetiologies, improving genetic diagnoses, and hearing restoration could alleviate this burden.

show abstract

Section: Methodsmentioning

confidence: 99%

Downward trends in the global burden of congenital complete hearing loss in children younger than five years from 1990 to 2030

Xiao,

Liu,

Cheng

et al. 2023

J Glob Health

Self Cite

View full text Add to dashboard Cite

show abstract

“…In this study, data on the disease burden of cSCC were obtained through an online query tool from the website of the Institute for Health Metrics and Evaluation (IHME) (https://ghdx.healthdata.org/). Te general methodology of GBD 2019 developed by IHME has been explained in the previous publications [7][8][9][10][11]. Tis study followed the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) reporting guideline for cross-section studies [12].…”

Section: Study Datamentioning

confidence: 99%

The Global, Regional, National Burden of Cutaneous Squamous Cell Carcinoma (1990–2019) and Predictions to 2035

Guo

Liu

et al. 2023

European Journal of Cancer Care

Self Cite

View full text Add to dashboard Cite

Objective. The aim of the study is to provide the burden of cutaneous squamous cell carcinoma (cSCC) in 21 regions, 204 countries, and territories from 1990 to 2019 by age, sex, and sociodemographic index (SDI) and to predict the global burden of cSCC to 2035. Methods. We use estimates from 2019 Global Burden of Disease (GBD) study to conduct the analysis and prediction. The burden of cSCC was estimated for 21 regions, 204 countries, and territories from 1990 to 2019, through a systematic analysis of incidence, death, and disability adjusted life years (DALYs) modelled data using the methods reported in the GBD 2019 study. We predicted the age-standardized incidence rates to 2035 at the global, regional, and national level. Results. There were 2,402,221 global incidence cases and 356,054 deaths in 2019. The age-standardized incidence rate was 30.3 and the age-standardized death rate was 0.7. cSCC, which caused 1.2 million DALYs with an ASR of 14.6 in 2019. Between 1990 and 2019, the age-standardized incidence rate increased by 36.1%, death rate increased by 6.1%, and DALY rate increased by 1.5% globally. At the regional level, the highest age-standardized incidence rate was found in high-income North America, the highest death and DALY rates were shown in Australasia. At the national level, Canada had the highest age-standardized incidence and DALY rates in 2019, and the highest death rate was shown in Tonga. A total of 11 GBD regions and 114 countries were predicted to increase in age-standardized incidence rates between 2019 and 2035, respectively. Conclusions. The cSCC is a major global public health challenge and the burden was often underestimated. The burden is increasing in most countries, especially in countries such as Canada, China, and regions such as Caribbean.

show abstract

“…Furthermore, it is estimated that the number of new cases is expected to exceed 1 million in 2020, with the number of deaths expected to exceed 500,000. Notably, Central Europe and Eastern Europe had the largest increased incidence among men over 55 years of age ( 2 , 3 ). In one study, ~75% of head and neck cancers overall are caused by tobacco smoking and alcohol abuse, with the remaining other ~25% attributable to HPV infection ( 4 , 5 ).…”

Section: Introductionmentioning

confidence: 99%

Clinical application of CT-based radiomics model in differentiation between laryngeal squamous cell carcinoma and squamous cell hyperplasia

Cui,

Khodrog,

Liu

et al. 2024

Front. Med.

View full text Add to dashboard Cite

ObjectiveTo evaluate the clinical application of the CT-based radiomics prediction model for discriminating SCC and SCH.MethodsA total of 254 clinical samples were selected from 291 patients with larynx-occupying lesions who underwent primary surgery. All lesions were validated via histopathological examination at The Second Hospital of Jilin University between June 2004 and December 2019. All patients were randomly allocated to the training (n = 177) and validation (n = 77) cohorts. After the acquisition of CT images, manual 3D tumor segmentation was performed using the CT images of the arterial, venous, and non-contrast phases via ITK-SNAP software. Subsequently, radiomics features were extracted using A.K. software. Based on the above features, three different diagnostic models (CTN, CTA+CTV, and CTN+CTA+CTV) were constructed to classify squamous cell carcinoma (SCC) and squamous cell hyperplasia (SCH). Additionally, receiver operating characteristic (ROC) and decision curve analysis (DCA) curves were measured to evaluate the diagnostic characteristics and clinical safety of the proposed three prognostic models.ResultsIn the radiomic prediction Model 1 (CTN), the area under the curve (AUC), accuracy, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the training cohorts in differentiating SCC and SCH were 0.883, 0.785, 0.645, 1.000, 1.000, and 0.648, while in the testing cohorts, these values were 0.852, 0.792, 0.66, 1.000, 1.000, and 0.652, respectively. In the radiomic prediction Model 2 (CTA+CTV), the AUC, accuracy, sensitivity, specificity, PPV, and NPV values of the training cohorts were 0.965, 0.91, 0.916, 0.9, 0.933, and 0.875, respectively, while in the testing cohorts, the corresponding values were 0.902, 0.805, 0.851, 0.733, 0.833, and 0.759, respectively. In the radiomic prediction Model 3(CTN+CTA+CTV), the AUC, accuracy, sensitivity, specificity, PPV, and NPV values of the training cohorts were 0.985, 0.944, 0.953, 0.929, 0.953, and 0.929, while in the testing cohorts, the corresponding values were 0.965, 0.857, 0.894, 0.8, 0.875, and 0.828, respectively.ConclusionThe radiomic prediction Model 3, based on the arterial-venous-plain combined scan phase of CT, achieved promising diagnostic performance, expected to be regarded as a preoperative imaging tool in classifying SCC and SCH to guide clinicians to develop individualized treatment programs.

show abstract

The global, regional, national burden of laryngeal cancer and its attributable risk factors (1990–2019) and predictions to 2035

Abstract: Objective: We aim to report the incidence, mortality and disability-adjusted life years (DALYs) between 1990 and 2019 and provide predictions to 2035.Methods: We use estimates from Global Burden of Disease, Injuries and Risk Factors Study 2019 to analyse the incidence, mortality and DALYs.

Cited by 14 publications

References 38 publications

Downward trends in the global burden of congenital complete hearing loss in children younger than five years from 1990 to 2030

Downward trends in the global burden of congenital complete hearing loss in children younger than five years from 1990 to 2030

The Global, Regional, National Burden of Cutaneous Squamous Cell Carcinoma (1990–2019) and Predictions to 2035

Clinical application of CT-based radiomics model in differentiation between laryngeal squamous cell carcinoma and squamous cell hyperplasia

Contact Info

Product

Resources

About